Grant of share options
18/07/2024 15:52
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240718:nRSR9963Wa&default-theme=true
RNS Number : 9963W Tissue Regenix Group PLC 18 July 2024
Tissue Regenix Group plc
('Tissue Regenix' or 'the Group')
Grant of share options
Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces
that Daniel Lee, Chief Executive Officer, and David Cocke, Chief Financial
Officer, have each been granted on 17 July 2024 an award of restricted share
units ("RSUs") and Kirsten Lund EMEA Business Director a Conditional Share
Award (CSA) with respect to ordinary shares in the capital of the Company
("Ordinary Shares") under the existing annual Tissue Regenix Share Incentive
Plan following the publication of the 2024 trading update.
Daniel Lee has been awarded 175,743 RSUs and David Cocke has been awarded
136,353 RSUs and Kirsten Lund has been awarded 49,798 Conditional Awards,
where each RSU/CSA that vests shall represent the right to receive payment of
one Ordinary Share. The exercise price of the RSUs is 0.1p per Ordinary Share.
The RSUs/CSA are subject to continued service over a period of three years and
satisfaction of customary performance conditions relating to growth in total
shareholder return, annual revenue targets, annual profitability targets and
personal performance targets.
Following the grant of these options, Daniel Lee and David Cocke hold options
over a total of 649,425 and 503,865 RSUs respectively representing 0.9% and
0.7% of the current issued share capital respectively. Kirsten Lund holds
options over a total of 185,796 CSA representing 0.3% of the current issued
share capital.
For more information:
Tissue Regenix Group plc www.tissueregenix.com (http://www.tissueregenix.com)
Daniel Lee, Chief Executive Officer via Walbrook PR
David Cocke, Chief Financial Officer
Cavendish Capital Markets Limited (Nominated Adviser and Broker)
Emily Watts/Geoff Nash/George Dollemore - Corporate Finance
Nigel Birks/Harriet Ward - ECM
Walbrook PR (Financial PR and IR) Tel: +44 (0)20 7933 8780
Charlotte Edgar / Alice Woodings TissueRegenix@walbrookpr.com
The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulation
'MAR' EU no.596/2014. Upon the publication of this announcement via the
Regulatory Information Service 'RIS', this inside information is now
considered to be in the public domain.
About Tissue Regenix (www.tissueregenix.com (http://www.tissueregenix.com) )
Tissue Regenix is a leading medical device company in regenerative medicine.
The Company's patented decellularisation technology (dCELL®) removes DNA and
other cellular material from animal and human soft tissue, leaving an
acellular tissue scaffold not rejected by the patient's body that can be used
to repair diseased or damaged body structures. Current applications address
many crucial clinical needs in sports medicine, foot and ankle injuries and
wound care.
Notification and public disclosure of transactions by persons discharging
managerial responsibilities ("PDMRs") and persons closely associated ("PCA")
with them.
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Daniel Lee
2 Reason for the notification
a) Position/status CEO
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Tissue Regenix Group plc
b) LEI 213800PNOD5UHQUFJI36
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Restricted share units ("RSUs") with respect to ordinary shares in the capital
of the Company of 0.1p
b) Identification code GB00B5SGVL29
c) Nature of the transaction Issue of options
d) Price(s) and volume(s) Volume(s):
175,743 RSUs
Price: 0.1 pence per RSU
d) Aggregated information
- Aggregated volume N/A
- Price
e) Date of the transactions 17 July 2024
f) Place of the transaction Outside of a trading venue
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name David Cocke
2 Reason for the notification
a) Position/status CFO
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Tissue Regenix Group plc
b) LEI 213800PNOD5UHQUFJI36
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Restricted share units ("RSUs") with respect to ordinary shares in the capital
of the Company of 0.1p
b) Identification code GB00B5SGVL29
c) Nature of the transaction Issue of options
d) Price(s) and volume(s) Volume(s):
136,353 RSUs
Price: 0.1 pence per RSU
d) Aggregated information
- Aggregated volume N/A
- Price
e) Date of the transactions 17 July 2024
f) Place of the transaction Outside of a trading venue
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Kirsten Lund
2 Reason for the notification
a) Position/status EMEA Business Director
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Tissue Regenix Group plc
b) LEI 213800PNOD5UHQUFJI36
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Conditional Share awards with respect to ordinary shares in the capital of the
Company of 0.1p
b) Identification code GB00B5SGVL29
c) Nature of the transaction Issue of options
d) Price(s) and volume(s) Volume(s):
49,798 CSAs
Price: 0.1 pence per SCA
d) Aggregated information
- Aggregated volume N/A
- Price
e) Date of the transactions 17 July 2024
f) Place of the transaction Outside of a trading venue
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHQKFBQQBKDFOD